Lisa Gill
JPMorgan Chase & Co, Research Division
Good morning, and thank you for joining us. My name is Lisa Gill, and I head up Healthcare Services at JPMorgan. It is with great pleasure this morning that we have with us Cencora. Presenting for Cencora will be CEO, Bob Mauch. In addition, we have Jim Cleary, CFO, who will join me for the Q&A session. With that, I’m going to turn it over to Bob.
Robert Mauch
President, CEO & Director
Thank you, Lisa. Hi, everyone. Thank you for being here. Thank you for your interest in Cencora. I’ll pause here for our cautionary note regarding forward-looking statements. And if you would like additional information, please go to our website at investor.cencora.com. So Cencora is a global pharmaceutical services health care company. We ship more than 1 billion medications yearly through our MSO investments. We have the #1 retina research network, 51,000 purpose-driven team members. And in the past year, we were fortunate to increase our revenue by 9% year-over-year and 16% for both our adjusted operating income and our adjusted diluted EPS, all while generating $3 billion in free cash flow.
Most importantly — or yes, most importantly, actually, we’re a purpose-driven company, and we’re united in our responsibility to create healthier futures, and that drives everything we do and is the leading indicator of those outcomes I just described. We’re very focused on being strategically disciplined and continuing to do that. We have 4 strategic drivers where we’re focused. One is our digital transformation, optimizing our business process, leveraging advanced analytics and AI to improve business
